Predicting patient response to gleevec in gastrointestinal stromal tumors

(Fox Chase Cancer Center) Researchers at Fox Chase Cancer Center uncovered a genetic pattern that may help predict how gastrointestinal stromal tumor patients respond to the targeted therapy imatinib mesylate. Moreover, their findings point to genes that could be suppressed in order to make these tumors respond more readily to imatinib.

source : www.eurekalert.org

Related News:

• UCLA School Of Dentistry To Build New Cancer Research Facility
• Elan revises J&J deal to appease Biogen
• MUHC/McGill researchers to WHO: Time to revise tuberculosis treatment guidelines
• Eli Lilly to cut 5,500 jobs by 2011
• New hospital, possible medical school attracting doctors to Merced
• Alcon to Acquire Swiss Biotechnology Firm, ESBATech AG
• Three SE distinguished alumni to be honored at homecoming
• Geriatric expert to speak at fundraiser
• JHSPH To Lead Extremity Trauma Clinical Research Consortium
• AOBO Launches New OTC Product To Treat Throat Inflammation

Details :
Submited at Tuesday, April 21st, 2009 at 4:00 pm on Cancer and Oncology by sofia
Comment RSS 2.0 - leave a comment - trackback